Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Anglia Ruskin University | OTHER |
Not provided
Not provided
Not provided
Over recent years there has been a lot of research looking at how the bacteria in our gut affects our health. Some medications are known to cause changes in gut bacteria.
Many patients that are prescribed iron report gastrointestinal side effects. This research project aims to see if the cause of the gastrointestinal side effects is due to iron causing changes in the gut bacteria. This can be detected via measuring the levels of hydrogen and methane and other compounds in the breath and stool.
Iron deficiency anaemia is the most common health issue worldwide, with approximately >1.2 billion people affected. In the UK, iron deficiency anaemia most commonly affects pre-school aged children and women aged 15-49 years. In 2011, an estimated 14% of non-pregnant, and 23% of pregnant women in the UK had iron deficiency anaemia, and 2-5% of male and post-menopausal women were also affected. Whilst compared to other areas of the world IDA has a mild public health significance to the UK, it can be the reason for up-to 13% of referrals to gastroenterologists.
Treating IDA with oral supplements or IV infusions are both effective at restoring bodily iron stores. However, success is often greater in those receiving their iron intravenously, due to frequent non-adherence to oral tablets as a result of their side effects. Gastrointestinal complaints, most commonly constipation, are reported by up to 60% of people that take oral iron supplements. These GI complaints causes up to 50% of patient to not follow their treatment plan, meaning their iron deficiency anaemia persists. However, patients that receive intravenous iron infusions instead do not report these symptoms. This suggests that oral iron has an impact on the GI tract as intravenous iron will bypass the gastrointestinal lumen but the mechanism of this remains uncertain.
To investigate the side effects of oral iron supplements and research a potential mechanism for the cause of iron supplement side effects, this study will require healthy volunteers to take ferrous sulphate for 4 weeks. Pre and post intervention participants will be required to provide a stool sample, complete a breath test and answer questionnaires.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ferrous Sulphate | Other | This is a single arm study, all participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lactulose breath test | Diagnostic Test | Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis. |
| Measure | Description | Time Frame |
|---|---|---|
| Breath methane levels | Difference in methane levels in breath samples from baseline and 4-weeks since commencing iron therapy. This will be measured in parts per million (ppm). | 4 weeks apart |
| Measure | Description | Time Frame |
|---|---|---|
| Volatile organic compounds (VOC) in breath | Difference in any breath gas markers. This is exploratory so will look to see what is present at baseline and see how it changes over the 4 week study period. | 4 weeks apart |
| Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Participant has no significant medical diagnosis or current or previous chronic gastrointestinal disease requiring medication or surgery (apart from appendectomy). Participant has no disease that would contraindicate iron supplementation e.g. haemochromatosis.
Participant is pregnant or breast feeding.
Participant takes medication known to impact the gut microbiome:
Participant is taking a regular prescription medication that has a contraindication with oral iron supplementation.
Participant has undergone a colonoscopy/sigmoidoscopy in the 1 week prior to enrolment.
Participant regularly consumes probiotics, prebiotics, fibre supplements in the 4 weeks prior to enrolment and/or is unwilling to exclude the use of probiotics from the diet during the study period.
Participant is involved in this study as an Investigator, sub-Investigator, study coordinator, other study staff, or sponsor member.
Participant has had previous abdominal or colorectal surgery except appendectomy or hysterectomy.
Participant has had oral iron supplementation of IV iron supplementation in the 12 months prior to enrolment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anthony Hobson | The Functional Gut Clinic | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Functional Gut Clinic | Cambridge | Greater Manchester | M2 4NG | United Kingdom | ||
| The Functional Gut Clinic |
Results will be written up and published in journal articles and presented at conferences
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003141 | Communicable Diseases |
| D018798 | Anemia, Iron-Deficiency |
| ID | Term |
|---|---|
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| C020748 | ferrous sulfate |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Stool sample | Other | Participants will provide a stool sample pre and post iron supplementation |
|
| Daily Diary | Other | Monitoring stool form, consistency and frequency on a daily basis |
|
| Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire | Other | Participants will complete the questionnaire pre and post iron supplementation |
|
| Ferrous Sulphate | Dietary Supplement | Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day. |
|
Comparison in change of IBS-SSS score from baseline to 4 weeks since commencing iron therapy. The minimum score is 0 and maximum score is 500. The greater the score, the worse the severity and frequency of symptoms of abdominal pain and distention, and increased dissatisfaction of overall bowel functioning. |
| 4 weeks apart |
| Stool consistency via the Bristol Stool Chart | Change in stool frequency and form according to the bristol stool chart scale from baseline to 4 weeks since commencing iron therapy. | 4 weeks apart |
| Gut Microbiome analysis via stool samples | Qualitative and Quantitative data for faecal microorganisms at baseline and 4-weeks since commencing iron therapy. | 4 weeks |
| Manchester |
| Greater Manchester |
| M3 4BG |
| United Kingdom |
| D000747 | Anemia, Hypochromic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D000090463 | Iron Deficiencies |
| D019189 | Iron Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |